NCT05409976进行中（未招募）不适用
Evaluation of the GORE® VIAFORT Vascular Stent for Treatment of Symptomatic Inferior Vena Cava Obstruction With or Without Combined Iliofemoral Obstruction
W.L.Gore & Associates33 个研究点 分布在 7 个国家目标入组 136 人开始时间: 2022年10月25日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 136
- 试验地点
- 33
- 主要终点
- Composite of efficacy and safety events
研究概览
简要总结
This study is a prospective, multicenter, non-randomized, single-arm study to evaluate the performance, safety, and efficacy of the GORE® VIABAHN® FORTEGRA Venous Stent (formerly known as GORE® VIAFORT Vascular Stent) for treatment of symptomatic inferior vena cava obstruction with or without combined iliofemoral obstruction in adult patients.
详细描述
A maximum of 35 clinical investigative sites across the U.S., Europe, Australia, and New Zealand will participate in this study. One hundred and eleven subjects are intended to be implanted with the GORE® VIABAHN® FORTEGRA Venous Stent (formerly known as GORE® VIAFORT Vascular Stent) in this study, with a limit of 22 treated subjects per site and a minimum of 45 patients treated within the United States. Subjects will be evaluated through hospital discharge and return for follow-up visits at 1, 6, 12, 24, 36, 48, and 60 months post-treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Preoperative Inclusion Criteria:
- •Patient is at least 18 years of age.
- •Patient is willing and able to comply with all follow-up evaluations as well as any required medication or compression regimen.
- •Patient is able to provide informed consent.
- •One of the following: Clinical severity class of CEAP 'C' classification ≥3 or rVCSS pain score ≥
- •Intention to treat the target areas with only the GORE® VIAFORT Vascular Stent.
- •Estimated life expectancy ≥1 year.
- •Patient is ambulatory (use of assistive walking device such as a cane or walker is acceptable).
- •Patient has adequate inflow to the target lesion(s), per investigator/sub-investigator discretion, involving at least a patent femoral or deep femoral vein.
- •Preoperative
排除标准
- •Patient is a pregnant or breastfeeding woman, a woman planning to become pregnant through the 12-month visit, or a woman who is unwilling to practice an acceptable method of preventing pregnancy through the 12-month visit.
- •Patient has clinically significant (e.g., symptoms of chest pain, hemoptysis, dyspnea, hypoxia, etc.) pulmonary embolism (confirmed via Computed Tomography Angiography) at the time of enrollment.
- •Patient has a known uncorrectable bleeding diathesis or active coagulopathy meeting the following definitions: uncorrected INR>2 (not as a result of warfarin or DOAC therapy), OR platelet count <50,000 or >1,000,000 cells/mm3, OR white blood cell count <3,000 or >12,500 cells/mm
- •Patient has impaired renal function (eGFR <30 mL/min/1.73m2) or is currently on dialysis.
- •Patient has uncorrected hemoglobin of <9 g/dL.
- •Patient has known history of antiphospholipid syndrome (APS) or patients with hypercoagulable states that are unwilling to take anticoagulant medications on a long-term basis.
- •Patient has known homozygous inherited coagulation defect or Protein C/S deficiency.
- •Patient has a planned surgical intervention (other than pre-stenting procedures such as thrombolysis or thrombectomy) within 30 days prior to or within 30 days after the planned study procedure.
- •Patient is currently participating in another investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the endpoints of this treatment, in the opinion of the investigator/sub-investigator. Observational studies are permitted.
- •Patient has had a previous major (i.e., above the ankle) amputation of the target lower limb.
- •Patient has known sensitivity to device materials or contraindication to antiplatelets, thrombolytics, anticoagulants (including patients with known prior instances of Heparin Induced Thrombocytopenia type 2 (HIT-2)), or iodinated contrast.
- •Patient has had prior stenting or grafts in the target vessels.
- •Patient has a known or suspected active systemic infection at the time of the index procedure. Patients with a chronic infection (e.g., HIV, hepatitis C) that is well controlled under their current treatment regimen may be eligible.
- •Patient has known history of intravenous drug abuse within one year of treatment.
- •Patient has significant peripheral arterial disease (chronic Rutherford Type 2 or greater, acute Rutherford Type IIa or greater).
- •Patient has a BMI >
- •Patient is actively undergoing or plans to begin cancer treatment.
- •Intraoperative Inclusion Criteria:
- •Presence of non-malignant obstruction of the inferior vena cava defined as occlusion or at least 50% reduction in target vessel lumen as measured by procedural IVUS and venogram, with or without non-malignant obstruction of the common femoral vein, external iliac vein, and/or common iliac vein.
- •Patient can accommodate an appropriately sized GORE® VIAFORT Vascular Stent as per reference vessel diameter (see IFU), as determined by intraoperative IVUS post pre-dilation.
- •Patient must have appropriate access vessels to accommodate the delivery sheath for the selected device size.
- •Patient has adequate landing zones free from significant disease requiring treatment within the native vessels beyond the proximal and distal margins of the lesion.
- •Patient has adequate inflow to the target lesion(s), per investigator/sub-investigator discretion, involving at least a patent femoral or deep femoral vein.
- •Lesion can be traversed with a guidewire.
- •Disease involves the inferior vena cava and may include iliofemoral segments with intent to stent all affected iliofemoral and caval segments.
- •Patient does not have significant (i.e., >20% residual thrombosis) acute thrombus within the target stent area at the time of investigational device placement. Patients with acute thrombus within the target stent area must have thrombus successfully treated prior to investigational device placement. Successful thrombus treatment is defined as reestablishment of antegrade flow with ≤20% residual thrombosis as confirmed by IVUS and venogram, AND freedom from bleeding, vascular injury, or hemodynamically significant pulmonary embolism. After successful thrombus treatment, investigational device placement can occur within the same procedure.
- •Patient does not have an inferior vena cava filter present within the target stent area at the time of investigational device placement. Patients with an inferior vena cava filter present within the target stent area must have the filter successfully removed prior to investigational device placement. Successful removal is defined as removal of the main body of the filter and intra-luminal fragments such that there is minimal risk to luminal integrity per investigator/sub-investigator discretion AND freedom from bleeding, vascular injury, or hemodynamically significant pulmonary embolism. After successful filter removal, investigational device placement can occur within the same procedure.
结局指标
主要结局
Composite of efficacy and safety events
时间窗: 12 months
Composite primary endpoint consisting of freedom from the following: * Loss of primary patency through 12-month follow-up * Stent embolization through 12-month follow-up * Device- or procedure-related death through 30 days * Clinically significant pulmonary embolism confirmed via Computed Tomography Angiography through 30 days * Device- or procedure-related vascular injury through 30 days requiring surgical or endovascular intervention * Device- or procedure-related major bleeding events through 30 days
次要结局
- Number of subjects with secondary patency as confirmed by imaging and adverse events(60 months)
- Revised Venous Clinical Severity Scale (rVCSS)(60 months)
- Technical success(Index procedure (post-op day 0))
- Number of subjects with device fracture as confirmed with imaging(60 months)
- Number of subjects with device- or procedure-related death(30 days)
- Number of subjects with primary patency as confirmed by imaging and adverse events(60 months)
- Number of subjects with device- or procedure-related vascular injury as confirmed with adverse events(30 days)
- Venous Insufficiency Epidemiological and Economic Study - Quality of Life/Symptoms (VEINES-QOL/Sym) VEINES-QOL/Sym(60 months)
- 5 Level EuroQol-5 Dimension (EQ-5D-5L)(60 months)
- Lesion success(Index procedure (post-op day 0))
- Number of subjects with clinically significant pulmonary embolism as confirmed with imaging and adverse events(30 days)
- Villalta(60 months)
- Number of subjects with clinically driven target lesion revascularization as confirmed by imaging and adverse events(60 months)
- Number of subjects with stent embolization as confirmed with imaging(12 months)
- Number of subjects with device- or procedure-related major bleeding events as confirmed with adverse events(30 days)
- Revised Venous Clinical Severity Scale (rVCSS) Pain(60 months)
- Procedural success(Index procedure through hospital discharge (discharge estimated as up to 30 days post-treatment))
研究者
研究点 (33)
Loading locations...
相似试验
进行中（未招募）
不适用
The GORE® VIABAHN® FORTEGRA Venous Stent Iliofemoral StudyVenous ThrombosesVenous DiseaseVenous Leg UlcerVenous StasisVenous UlcerVenous StenosisVenous OcclusionVein ThrombosisVein OcclusionVein DiseaseNCT05489588W.L.Gore & Associates165
已完成
2 期
Evaluation of the GORE® ACUSEAL Vascular Graft for Hemodialysis AccessEnd Stage Renal DiseaseNCT01173718W.L.Gore & Associates138
已完成
不适用
Evaluation of the GORE TIGRIS Vascular StentPeripheral Arterial DiseaseNCT01576055W.L.Gore & Associates267
已完成
不适用
Efficacy and Safety of GENOSS® DES in Patients with Coronary Artery DiseaseCoronary Artery DiseaseNCT06066476Genoss Co., Ltd.1,022
已完成
3 期
Cobalt Chromium Stent With Antiproliferative for Restenosis II Trial (COSTAR II)Coronary DiseaseNCT00165035Cordis Corporation1,701